Drug intelligence / Profile preview

methanobactin

Development stage: Preclinical
Lead developer: Arbormed
Modality: Peptides, Small Molecules
Administration: Parenteral

Overview

Methanobactin (HY-106) is a small molecule, copper-selective chelator being developed by Hyloris Developments. Originally identified as a "chalkophore" produced by methanotrophic bacteria (such as *Methylosinus trichosporium* OB3b) to acquire copper, it is being repurposed as a therapeutic agent for disorders of metal metabolism. The drug is currently in preclinical development for the treatment of Wilson's disease, cholestatic liver fibrosis, and iron overload. Its exceptionally high affinity and selectivity for copper allow it to mobilize and remove toxic copper deposits from the liver and other tissues, potentially offering a more potent and rapid-acting alternative to traditional chelators like D-penicillamine or trientine.

Other names: methanobactin

Beyond the preview

Go deeper on methanobactin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methanobactin.

Explore the full profile